MedTrace Logo

NAFLD in Patient of Hypothyroidism

NCT05813301 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-04-14

No results posted yet for this study

Summary

Nonalcoholic fatty liver disease (NAFLD) is the most important chronic liver disease in the western world, affecting almost 30% of the general population. Moreover, the prevalence of NAFLD can be higher in type 2 diabetic patients and obese patients, affecting up to 90% of people with a body mass index higher than 40 kg/m2. NAFLD is also the most rapidly increasing cause of hepatic cirrhosis requiring hepatic transplantation in the future. The pathophysiology of NAFLD is complex and involves multiple hits, but the principal contributing factor to its development is hepatic lipid accumulation, which leads to hepatic insulin resistance

Conditions

  • NAFLD

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • wael ahmed abbas, prof · Assiut University

  • walaa anwer shehata, prof · Assiut University

  • mena sawerss fathy, residant · Assiut University

Eligibility

Min Age
10 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-12-01
Completion
2026-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813301 on ClinicalTrials.gov